Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIVA: Perioperative NASOX vs gemcitabine + S-1/S-1 in resectable pancreatic cancer
jRCTs031250644Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of nanoliposomal irinotecan, oxaliplatin, gemcitabine and tegafur in pancreatic cancer (PC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Safety run-in adverse events during preoperative NASOX, Safety run-in intraoperative complications and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatingemcitabinetegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs031250644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250644.